stars 1 stars 2 stars 3

ReceptorPharma has the goal to develop new Alzheimer’s drugs through a completely new pathway and mechanism. We are utilizing the very latest research and findings regarding disease-coupled genes and combining it with the usage of one of the most well-studied drug target protein families. This novel approach to create a new generation of Alzheimer’s disease drugs that act through is our competitive advantage and where our competences shine. In addition to Alzheimer’s disease, our approach will allow for the development of new drugs for several additional debilitating diseases, including certain types of cancer, through similar mechanisms using disease-coupled as drug targets.

ReceptorPharma Inc Questions

The ReceptorPharma Inc annual revenue was $4 million in 2026.

ReceptorPharma Inc is based in Dover, Delaware.

The NAICS codes for ReceptorPharma Inc are [5417, 541, 54, 54171, 541714].

The SIC codes for ReceptorPharma Inc are [87, 873].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users